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Abstract
Monoclonal antibodies directed against hepatitis C virus (HCV) E2 protein can neutralize cell-cultured HCV and
pseudoparticles expressing envelopes derived from multiple HCV subtypes. For example, based on antibody blocking
experiments and alanine scanning mutagenesis, it was proposed that the AR3B monoclonal antibody recognized a
discontinuous conformational epitope comprised of amino acid residues 396–424, 436–447, and 523–540 of HCV E2
envelope protein. Intriguingly, one of these segments (436–447) overlapped with hypervariable region 3 (HVR3), a domain
that exhibited significant intrahost and interhost genetic diversity. To reconcile these observations, amino-acid sequence
variability was examined and homology-based structural modelling of E2 based on tick-borne encephalitis virus (TBEV) E
protein was performed based on 413 HCV sequences derived from 18 subjects with chronic hepatitis C. Here we report that
despite a high degree of amino-acid sequence variability, the three-dimensional structure of E2 is remarkably conserved,
suggesting broad recognition of structural determinants rather than specific residues. Regions 396–424 and 523–540 were
largely exposed and in close spatial proximity at the surface of E2. In contrast, region 436–447, which overlaps with HVR3,
was .35 A ˚ away, and estimates of buried surface were inconsistent with HVR3 being part of the AR3B binding interface.
High-throughput structural analysis of HCV quasispecies could facilitate the development of novel vaccines that target
conserved structural features of HCV envelope and elicit neutralizing antibody responses that are less vulnerable to viral
escape.
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Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen that
chronically infects more than 125 million people worldwide [1].
Long-term HCV infection is associated with liver cirrhosis,
hepatocellular carcinoma, and end-stage liver disease [2]. HCV
is genetically diversified: it is classified into 6 major and .100
minor subtypes [3] and exists as a quasispecies within infected
subjects [4,5]. This high degree of genetic variability is thought to
contribute to the persistence of HCV infections and to the
pathogenesis of hepatitis C [6]. A large share of HCV sequence
variation is concentrated within hypervariable regions of the E2
envelope gene, including hypervariable region 1 (HVR1), a
sequence of 27 amino acids located at the N-terminus of E2
(amino acid residues 384–410) [7]. A second hypervariable cluster,
termed HVR2, is located downstream from HVR1 (amino acid
positions 474–482) [8,9]. Finally, a third hypervariable region
(HVR3) positioned in between HVR1 and HVR2 (amino acid
residues 431–466) [10] was recently integrated in the canonical
model of E2 structure [11–14]. Solvent exposure and the
conservation of overall conformation and specific amino acid
residues at specific positions of HVR1, HVR2, and HVR3 are
consistent with roles in target cell recognition, virus attachment,
and cell entry [10,15]. As HCV E1 and E2 envelope glycoproteins
are important targets for host humoral and cell-mediated immune
responses, hypervariable regions are also subjected to robust levels
of selective pressure (HVR1..HVR3.HVR2) [10,16,17].
There is little evidence to link HCV-specific immunoglobulin
(Ig) responses, spontaneous HCV clearance, and clinical progres-
sion of hepatitis C [18–20]. However, recently-published data
based on cell-cultured HCV (HCVcc) and HCV pseudoparticles
(HCVpp) indicate that broad antibody-mediated neutralization of
HCV virions can in fact be achieved using human monoclonal
antibodies (hMAbs) directed against epitopes located within HCV
envelope proteins [21]. This and other reports [22–30] led to a
shift in paradigm and have rekindled interest in HCV-specific
neutralizing antibody responses. In some cases, HCV neutraliza-
tion is thought to result from binding of E2 determinants that are
critical for interaction with tetraspanin CD81 and/or scavenger
receptor class B I (SR-BI) [22–25], two cell-surface molecules that
are thought to be involved in attachment and entry of HCV into
the host cell [31,32]. Of particular interest, Law et al. reported that
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26981the AR3B hMAb was able to neutralize HCVcc and HCVpp
expressing envelopes from multiple HCV subtypes and protect
human liver-chimeric Alb-uPA/SCID mice against challenge with
a heterologous HCV quasispecies [14,33]. Based on antibody
blocking experiments and alanine scanning mutagenesis, it was
proposed that AR3B recognized a discontinuous conformational
epitope comprised of E2 amino acid residues 396–424, 436–447,
and 523–540. Intriguingly, one of these segments (436–447)
overlaps with HVR3, a domain that exhibits significant intrahost
and interhost amino-acid variability (Figure 1) [10]. To address the
fundamental basis underlying the capacity of hMAbs such as
AR3B to neutralize a heterogeneous quasispecies, E2 amino-acid
sequence variability was examined and homology-based three-
dimensional modelling of E2 based on tick-borne encephalitis virus
(TBEV) E protein structure was performed using 413 HCV
sequences derived from 18 subjects with chronic hepatitis C and
111 HCV sequences derived from reference sets. Here we report
that regardless of a high degree of amino-acid sequence variability,
the overall predicted structure of E2 was remarkably conserved,
consistent with broad recognition of structural determinants rather
than specific amino acid residues.
Results
HCV E2 amino-acid sequence variability was examined in HCV
quasispecies derived from 17 HCV-infected subjects, 4 of whom
were tested at two different time points (i.e. during the course of two
consecutive pregnancies) (n=21) (Figure 1) [10]. E2 sequences
derived from the single HCV-1a-infected serum donor from the
original report on AR3B-mediated HCV neutralization were also
included in the analysis [14]. In the large majority of cases, pairwise
protein pdistancescomputedoveraregionofE2that comprised the
AR3B-defined neutralizing epitope (i.e. amino acid residues 384–
508) indicated extensive amino-acid sequence variability
(Figure 2A). Potential associations between protein p distances
and clinical parameters measured among study subjects were
examined. No statistically significant correlations were found
between median pairwise p distances and: a) HCV viral load in
terms log10 IU per ml plasma (p=0.1033, r=0.2950; Spearman’s
correlation test); b) circulating aspartate aminotransferase (AST)
levels (p=0.4419, r=0.03599; Spearman’s correlation test); or c)
alanine aminotransferase (ALT) levels (p=0.3974, r=20.06395;
Spearman’s correlation test) (data not shown). Based on previous
analysis [10] and data obtained in the present study, one plausible
hypothesis to explain these findings would be that the dispersion in
protein p distances reflects a manifestation of viral neutralization
escapeandselectivepressureexertedon the viral quasispeciesbythe
shifting of host HCV-specific immune responses in terms of
antigenic specificity, scope, and magnitude. These could include
neutralizing antibody responses directed against HCV E2 envelope
protein and/or antibody-dependent cellular cytotoxicity (ADCC).
In 9 of 21 cases (42.9%), median pairwise p distances were equal or
significantly lower than that observed in the HCV-1a-infected
serum donor (p,0.001, Kruskal-Wallis test with Dunn’s post test).
This suggests that AR3B-mediated neutralization of this particular
HCV isolate in chimeric Alb-uPA/SCID mice, as reported by Law
Figure 1. HCV E2 amino-acid sequence variability in HCV quasispecies derived from HCV-infected subjects. A. Consensus E2 amino-
acid sequences were determined in 17 HCV-infected subjects and in the HCV-1a infected serum donor from ref. 14 based on the identity of the most
frequent amino-acid residue at each position. 1: R or H; 2: V or I; 3: A or T; 4: R or Q. B. Variability at each amino acid position was computed using the
Entropy-ONE Web tool [58]. C. Amino-acid segments that were shown to be important for binding of the AR3B antibody [14].
doi:10.1371/journal.pone.0026981.g001
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quasispecies. Consistent with the fact that AR3B recognized HCV
E2 in its native conformation and not under denaturing conditions,
these observations further suggest that the specificity of AR3B could
result from broad recognition of HCV E2 structural determinants
rather than specific amino acid residues.
To test this hypothesis, homology-based structural modelling of E2
based on tick-borne encephalitis virus (TBEV) E protein (PDB ID
1SVB) was performed as previously described [10,34,35]. Separate
structures were generated based on i) 391 different E2 amino acid
sequences derived from 17 HCV-infected patients (see above) [10]; ii)
22 different E2 amino acid sequences derived from a serum donor
infected with HCV-1a [14]; and iii) a set of 111 E2 reference
sequences that comprised representatives of all 6 major HCV
subtypes (http://hcv.lanl.gov/content/hcv-db/) [36]. The resulting
524 models were then individually compared to an E2 structure
based on an HCV-1a reference sequence (GenBank accession no.
M62321) using the secondary structure matching algorithm (SSM)
[37]. Structural differences were expressed as root mean square
deviations (RMSD), which represent the mean deviations in A ˚
between paired protein backbones. Median RMSD values computed
based on variants from the HCV-1a-infected serum donor were not
significantly different from those obtained based on sequences from
14 of 21 (66.7%) HCV-infected sera tested [10] (p.0.05, Kruskal-
Wallis test with Dunn’s post test), indicative of extensive structural
conservation throughout the proposed AR3B-binding domains in
HCV-infected subjects (Figure 2B). Infection with HCV genotypes 2r
(subject TV531; presence of a 2 amino acid insertion in E2) or 3a
Figure 2. E2 amino-acid sequence variability and structural conservation across HCV subtypes and quasispecies. A. Pairwise protein p
distances analysis in HCV-infected subjects revealed wide disparities in E2 (residues 384–508) amino-acid sequence variability. All patients were
infected with HCV-1 except TV531, who was infected with HCV-2r, and TV453, TV45, and TV73, who were infected with HCV-3a (shaded bars). B. The
majority of HCV-infected subjects showed minimal structural deviation from the E2 reference structure. Asterisks (*) indicate RMSD values associated
with singular outlier structures that were observed in subjects TV531 and TVC73, but not in any other subjects. C. Modelled E2 structures from HCV-
infected patients from our study group (n=391) [10] and from the HCV Database Project (genotype 1; n=90 sequences) [36] showed less than 1 A ˚
deviation from the reference structure. Structures based on HCV genotypes 2–6 (n=21 sequences) [36] also showed minimal structural variation. p:
protein pairwise p distance. RMSD: root-mean-square deviation. Asterisks indicate RMSD values associated with these single outlying structures.
doi:10.1371/journal.pone.0026981.g002.
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which statistically significant structural differences were observed as
compared with models based on E2 sequences from the HCV-1a-
infected serum donor (Figure 2B). As above, potential associations
between median RMSD and clinical parameters were examined
among study subjects. There was no statistically significant
correlations between median RMSD and: a) HCV viral load
(p=0.1675, r=0.2274; Spearman’s correlation test); b) circulating
AST levels (p=0.2856, r=0.1387; Spearman’s correlation test); or c)
circulating ALT levels (p=0.4472, r=20.01408; Spearman’s
correlation test) (data not shown). Comparatively larger ranges in
RMSD values were obtained when larger datasets were examined,
including pooled sequences from the 17 HCV-infected subjects
(n=391) [10], HCV-1 reference sequences (n=90) [36], and
reference sequences from HCV subtypes 2–6 (n=21) [35]
(Figure 2C). However, median RMSD values were not significantly
different between these 4 groups (p.0.05, Kruskal-Wallis test with
Dunn’s post test). It should be pointed out that although larger ranges
of variance were found in the pooled samples, the differences are still
of less than one A ˚ (Figure 2). Interestingly, there was no correlation
between median p distanceand median RMSD among study subjects
(p=0.4989, r=20.0006584; Spearman’s correlation test) (data not
shown). Therefore, E2 structural heterogeneity in individual HCV-
infected subjects was not predicted by E2 amino acid sequence
variability (Figure 2A and 2B).
Consequently, to understand the origin of E2 structural
heterogeneity amongst quasispecies in these patients, E2 structural
models(n=391) and the E2referencestructure(GenBank accession
no. M62321) were compared between each other and a RMSD
distance matrix wascomputed. To betterillustrate the relatedness of
these multiple individual models, a dendrogram representing HCV
E2 structure distribution was generated based on this matrix using
the neighbor-joining method [38] (Figure 3). E2 structures from
HCV genotype 1 formed a very tight cluster (0.13 A ˚ diameter),
indicative of significant structural similarity, while structures
modelled based on sequences from subjects infected with HCV
genotype 3a were more broadly distributed (0.73 A ˚ diameter)
(Figure 3A). In subjects TV531 (HCV-2r) and TVC73 (HCV-3a),
singular outlier structures based on E2 sequences that exhibited
insertions of two amino acid residues markedly diverged from
structures modeled according to the sequence of other variants
present in the same patients or sequences derived from other study
subjects (Figure 3A). In contrast, when cladograms were computed
based on nucleotide sequence data, these outliers invariably
clustered with sequences from the same patients (bootstrap values
.80%) (Figure 4). The apparent intrahost structural homogeneity
of E2 and scarcity of outlier structures suggest that these could be
the result of poorly-conserved mutations negatively affecting HCV
replicative fitness. Alternatively, these outliers might represent
newlyemerged viralvariantsthatescaped host humoraland/orcell-
mediated immune responses [23,29,39]. E2 structures from subjects
infected with genotype 1a or 1b clustered in a subtype-specific
manner (Figure 3B). Subjects TV179 and TVC55 showed some
divergent structures which could explain the larger range of
similarities with the reference structure found in these patients
(Figure 2B and 3B). These results suggest that E2 segments that
comprise HVR3 exhibit a high degree of amino acid sequence
variability while at the same time retaining a well-conserved
structural framework, possibly related to their putative function(s) in
HCV E2 conformation, E1–E2 dimerization, and/or viral entry
into target cells [40].
Since the effectiveness of AR3B in neutralizing HCV quasis-
pecies may depend on its capacity to target conserved structural
patterns, molecular modeling was used to examine the putative
Figure 3. Dendrogram of E2 structure clustering in HCV quasispecies derived from HCV-infected subjects. A. Analysis of the structural
distance (RMSD) matrix of modelled E2 structures from HCV-infected subjects (n=391) using the neighbour-joining algorithm showed a clustering of
genotype 1 variants (boxed), with the exception of singular outlier structures (circled) and genotype 3a variants. B. Subtype 1a and 1b clustered
separately but were structurally similar. E2 structures derived from patients infected with the same HCV subtype formed distinct clusters.
doi:10.1371/journal.pone.0026981.g003
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ity calculations [10], segments that comprised amino-acid
positions 396–424, 436–447, and 523–540 were predicted to be
largely exposed at the surface of E2. Interestingly, regions 396–424
and 523–540 were predicted to lie in close spatial proximity and
several amino acids that were identified in mutagenesis and
antibody-blocking experiments as crucial residues for AR3-specific
antibody recognition (i.e. Gly 530, Asp 535, and Val 538) were
grouped within a 10.9 A ˚ radius around Ser 424 (Figure 5). In
sharp contrast, region 436–447, which overlaps with HVR3, is
more than 35 A ˚ away. According to this model, simultaneous
binding of segments 396–424, 436–447, and 523–540 by a single
immunoglobulin molecule would involve an interface area
covering more than 1000 A ˚ 2 (Figure 5). In contrast, typical values
Figure 4. Phylogenetic analysis of HCV quasispecies derived from HCV-infected subjects. 391 independently-obtained HCV E2 nucleic
acid sequences derived from HCV-infected subjects were analyzed using the neighbor-joining method, as described under Materials and Methods.
500 bootstrap re-samplings were performed to ascertain tree topology. Scale bar represents 0.1 nucleotide substitution per site.
doi:10.1371/journal.pone.0026981.g004
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560 A ˚ 2 and 855 A ˚ 2 [41]. Therefore, it is unlikely that the AR3B
binding site on E2 encompasses HVR3 as previously suggested
[14]. Instead, it is possible that binding of HVR3 by the 2/69A
and 11/20 monoclonal antibodies but not 1/39 and 7/16B, all
four of which map between amino acid residues 432 and 447 [14],
induced conformational changes in E2 that inhibited AR3B
interaction with its distal cognate binding sites.
Discussion
In the present study, E2 sequences and structures from 524 HCV
variants were examined using a secondary-structure graph-
matching algorithm and displayed using a novel dendrogram-based
graphical representation,allowing the rapidandprecisecomparison
of hundreds of tri-dimensional structures. As similarities between
large numbers of proteins could be assessed in an effort to identify
common structural motifs, this high-throughput approach was
particularly useful for the inspection of HCV quasispecies resulting
from the high replication rate of HCV and the lack of proofreading
activity of its RNA-dependent RNA polymerase. Overall, this
analysis revealed that the primary amino-acid sequence of E2 was
extremely diversified. This is consistent with the fact that E2 is
exposed to significant selective pressure in vivo, and that continual
amino acid sequence variation is associated with rounds of escape
from host humoral and cell-mediated immune responses [42]. In
contrast, the tridimensional structure of E2, including that of
HVR1, HVR2, and HVR3, was largely maintained and showed
little variation, except in the case of a limited number of outlier
variants. In addition, estimates of buried surface were inconsistent
with HVR3 being part of the AR3B binding interface. From these
data, we propose that the broad recognition of E2 by MAb such as
AR3B could result from their ability to target conserved structural
conformations shared by multiple HCV variants rather than highly
variable linear epitopes. Alternatively, AR3B neutralizing activity
could be relatedto the preventionof a conformational change in the
envelope protein that would be required for exposing a putative
fusion peptide. Indeed, according to a recently-proposed model of
E2 structure based on the conservation and positioning of
intramolecular disulfide bonds [43], HVR3 (431–466) would
straddle the « central » domain (DI) of E2, that participates in
binding to CD81, and domain DII which is thought to comprise the
putative fusion loop. In addition, based on testing of genotypic
incompatibility in intersubtype chimeras, a portion of HVR3
Figure 5. Putative binding site of the AR3B monoclonal antibody on E2. A. Structural analysis of the proposed AR3B binding site on E2
(orange, red, and green) revealed that it would bury between 1092 and 1794 A ˚2 at the surface of E2. Regions 396–424 (red) and 523–540 (orange) are
closely associated compared with region 436–447 (green). B. Analysis of the 396–424 and 523–540 regions (magnified) showed that critical residues
involved in AR3B binding (Ser 424, Gly 530, Asp 535 and Val 538) were largely surface-exposed and lied in close proximity to one another.
doi:10.1371/journal.pone.0026981.g005
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[44]. Finally, in other Flaviviridae such as Dengue virus and TBEV,
the native E protein is found as a dimer arranged in a « herringbone
pattern » at the surface of the virion [45,46]. Although we were
unable to reliably model the putative dimer interface, an intriguing
possibility would be that the conformational epitope recognized by
AR3B actuallyspansbothprotomersinthenativeE2dimer,leading
to HCV neutralisation.
In humans, the majority of antibodies target discontinuous or
conformational epitopes. Yet, most studies on B cell responses in
HCV-infected patients have focused on the characterization of
linear epitopes [47]. Characterization of antibodies with broad
neutralization capacities and their conformational epitopes could
lead to a better understanding of the fundamental basis for broad
recognition of viral proteins with high amino-acid variability. Such
broadly-neutralizing MAbs could be used as prophylaxis to
prevent re-infection of the incoming organ in subjects undergoing
liver transplant as a consequence of chronic hepatitis C [48].
While technically challenging, studies on conserved structural
features of HCV envelope proteins could lead to the design of
peptide-based structural mimics [49], which could in turn be used
to elicit neutralizing–and potentially protective–antibody respons-
es that are less vulnerable to mutational escape.
Materials and Methods
Ethics statement
This research protocol was conducted in full compliance with
the Declaration of Helsinki and was approved by « le Comite ´
d’e ´thique de la recherche du CHU Sainte-Justine », Montreal,
Canada, where the study was conducted. Written informed
consent was obtained from all study participants. All subjects
and their children were provided with medical care and
counselling required by their condition.
Study subjects and clinical parameters
Study subjects (n=17) were participants to the Centre maternel
et infantile sur le SIDA mother-child cohort (CHU Sainte-Justine,
Montreal,Canada)and werepreviouslyenrolledinastudyofHCV-
specific immune responses and HCV quasispecies evolution during
pregnancy [10,50]. Serum was extracted from whole blood by
centrifugation and was kept at 280uC until used. ALT and AST
levels were measured on a Synchron LX20 system (Beckman
Coulter). Normal ALT and AST levels were 5–34 U/l and 11–43
U/l, respectively. Plasma HCV RNA levels were quantified using
the COBAS Amplicor HCV Monitor assay version 2.0 (Roche
Diagnostics). HCV genotyping was performed by sequence analysis
of the 59 non-coding region and NS5B, as described [51]. From
these patients, 391 nucleotide sequences of E2 (mean of 23
sequences per subject; range=17–38) were obtained and used for
the analysis of amino acid variability, as previously described
(GenBank accession no. DQ650805–DQ652141) [10]. Briefly, viral
RNA was extracted from serum, and a portion of the E1 and E2
genes from HCV genotype 1 (nucleotide positions 1278–1889) was
amplified by RT-PCR using the OneStep RT-PCR method
(QIAGEN) and previously-published amplification conditions
[10]. Primers E2/NS1a and E2/NS1b [52] were used to amplify
HCV-1a and HCV-1b, while primers E2/NS5aBIS [10] and E2/
NS1b were used for subject TVC55, and primers E2/NS3a and
E2/NS1b or E2/NS3b [10] were used for subjects infected with
HCV-3a. Because the mutation rate associated with the use of a
non-proofreading polymerase is known to be largely unbiased with
respect to the localization of mutations within amplified segments,
comparisons between regions located within single amplicons were
considered valid [53]. PCR products were purified from agarose
gels and cloned in pCR2.1-TOPO (Invitrogen). DNA sequencing
was performed on a Genetic Analyser 3100 (Applied Biosystems)
using dye terminator chemistry. Chromatograms were edited
manually using Chromas version 1.45 (Technelysium). Pairwise
protein p distances were calculated using MEGA version 4.0 [54].
Structural analysis of E2
Homology-based structural modelling of E2 based on TBEV E
protein was performed as previously described [10]. Five hundred
and twenty four separate structures were generated based on i) 391
different E2 amino acid sequences derived from 17 HCV-infected
patients [10]; ii) 22 different E2 amino acid sequences derived
from the HCV-1a serum donor described in reference [14]; and
iii) a group of 111 E2 reference sequences that comprised
representatives of all 6 major HCV subtypes [36]. Secondary
structure predictions were used to align HCV E2 sequences with
TBEV E protein, and the alignment was used to model E2 using E
protein structure (PDB ID 1SVB) [34,35] using MODELLER
[55]. Energy minimization was performed using 100 steps of the
steepest descent algorithm and CVFF [56]. Protein structures were
visualized with PyMOL V1.3 (http://www.pymol.org). Resulting
models were then individually compared to an E2 structure based
on an HCV-1a reference sequence (GenBank accession no.
M62321) using the SSM algorithm [37]. This procedure matches
graphs built on the protein’s secondary-structure elements
followed by an iterative three-dimensional alignment of protein
backbone ca atoms based on geometrical position rather than
biochemical properties, allowing a precise assessment of proteins
structural similarities in three dimension [37]. The 391 E2
structures from HCV-infected patients and E2 reference structure
were also compared among themselves using SSM, resulting in a
392 by 392 structural distance matrix. Structural differences were
expressed as root mean square deviations (RMSD), which
represent the mean deviation in A ˚ between paired protein
backbones. Analysis of the structural distance (RMSD) matrix
was performed using the neighbour-joining method [38], as
implemented in MEGA version 4.0 [54].
Phylogenetic analysis
HCV E2 sequences derived from 17 HCV-infected subjects
(n=391) were aligned using ClustalX 2.0.11 [57]. Kimura 2-
parameter distance matrices were assembled and phylogenetic
reconstructions were built according to the neighbour-joining
method using MEGA [38,54]. 500 boostrap resampling were used
to assess the robustness of tree topology, with values .80%
considered significant.
Statistical analysis
Differences between groups were tested using the Kruskal-
Wallis test with Dunn’s post test. Correlation coefficients were
computed using Pearson’s test. All statistical analysis was
performed using GraphPad Prism version 4 (GraphPad Software).
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